DATAR - exacta
THE MOST COMPREHENSIVE INVESTIGATION OF TUMOURS
Exacta is a comprehensive analysis of the molecular-genetic characteristics of solid tumours, based on the results of several clinical studies.
Especially in rare solid tumours for which no guidelines are available, in advanced disease or in difficult-to-treat tumours, Exacta offers an advantage.
Exacta analyses millions of data points at the molecular level to identify all relevant targets for individual therapy.
Exacta is particularly recommended for cancer patients where:
...the initial therapy has failed
...a relapse has occurred
...the cancer is high-grade or metastatic
...are diagnosed with complex cancers such as stomach, oesophagus, pancreas, gallbladder, GIST, etc.
...the risk of treatment failure is high
No queues
Results in 10-14 days
Faster recovery
Experienced specialists
About the exacta test
The conventional “Standard of Care” approach does not take into account the full genetic architecture of a given patient’s tumour.
As a result, patients may suffer from failed therapies or aggressive disease recurrence.
It is therefore essential that the molecular architecture of the tumour is thoroughly studied before a treatment plan is defined, which must be tailored to the individual patient and their disease.
Exacta is a comprehensive and in-depth analysis of tumour gene expression.
It analyses hundreds of millions of data points at the molecular level to uncover all possible targets for precision medicines.
Exacta helps to uncover the mutations that drive cancer and the pathways that promote the development of the disease through multi-analytic and multi-coordinate analysis of over 20,805 genes in the cancer genome.
This analysis helps to identify the drugs that would be most effective for a given solid tumour.
Exacta thus enables a highly sophisticated treatment strategy that goes beyond conventional approaches, even for difficult-to-treat or late-detected cancers.
Benefits
Exacta identifies potential molecular targets and cell cycle pathways to find the most suitable molecular targets for targeted therapy.
All relevant biomarkers for target therapy selection are analysed, including mutations, deletions, gene rearrangements, gene amplification/expression.
Blood collection: 40 ml of blood in STRECK and EDTA tubes. Optional: 40 ml blood in STRECK and EDTA tubes and fresh tissue sample in DCGL transport medium (4-6 cm3 or 5 nuclei); alternative: FFPE tissue block
Warnings:
Wait 24 hours after chemotherapy/PET-CT/MRI before coming for a blood test.
Wait 10 days after the blood transfusion.
Processing time: 10 – 14 days from receipt of sample.
Frequently asked questions
If two patients have the same histopathological type of cancer and one of them has an exacto analysis, can the other patient receive the same treatment as the first? Just as every patient is unique, every cancer is unique.
No two cancers are exactly the same.
Even two similar patients (e.g. age, sex, height, lifestyle) with the same type of cancer will have different tumour molecular profiles.
Therefore, each patient must undergo an individual exacta test.
Why is it important to start treatment immediately? Cancer can be very aggressive and can develop rapidly; the tumour profile can change drastically over time.
If there is a long delay, the cancer may become resistant to treatment and may need to be re-analysed.
What medicines will be recommended to the patient? Only FDA-approved medicines will be recommended and used.
These will include drugs that are approved for use in the same cancer, another cancer or other non-carcinogenic diseases.
Are there further molecular tests to assess the results of the recommended therapy? Molecular tests such as our cancertrack assay allow the oncologist to monitor therapy in real time.
In addition, the test provides insight into the genetic changes of the original tumour so that therapy can be tailored accordingly.
